Frequency and site mapping of HIV-1/SIVcpz, HIV-2/SIVsmm and other SIV gene sequence cleavage by various bacteria restriction enzymes: Precursors for a novel HIV inhibitory product

African Journal of Biotechnology

Volumn 6, Issue 10, 2007, Pages 1225-1232

  Misaki, Wayengera ^a   Wilson, Byarugaba ^b   Henry, Kajjumbula ^b  

^a MaRS Discovery District of T TO ^*  (Canada)

^b MAKERERE UNIVERSITY   (Uganda)

Author keywords

Combination microbicides; HIV genomes; HIV AIDS; Novel microbicides strategies; Restriction modification systems

Indexed keywords

RESTRICTION ENDONUCLEASE;

ARTICLE; BACTERIAL CHROMOSOME; CHROMOSOME ANALYSIS; COMPUTER SIMULATION; GENE FREQUENCY; GENE MAPPING; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; NUCLEOTIDE SEQUENCE; REFERENCE DATABASE; RESTRICTION MAPPING; VIRUS GENOME; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 34249790580     PISSN: None     EISSN: 16845315     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Anastasopoulo KG, Marozsan AJ, Matet A, Snyder AD, Arts EJ, Kuhmann SE, Moore JP (2006). Variants of differing replication capacity (fitness) co-exist in the quasispecies populations of viruses resistant to a small molecule CCR5 inhibitor. Program and abstracts of the 16th International AIDS Conference; August 13-18, Toronto, Canada. Abstract WEPE0005.
2. Barcus VW, Murray N (1995). Barriers to recombination. In S. Baumberg, J Young, E Wellington and J Saunders(eds) Population genetics of bacteria; Cambridge University Press, Cambridge. pp. 31-38.
3. Barichievy S, Carmona S, Crowther C, Saayman S, Morris K, Arbuthnot P, Weinberg M (2006). Post-transcriptional inhibition of HIV-1 subtype C by expressed long hairpin RNAs targeted to the R and U5 regions of the LTR, Abstract MOPDA02, 2006 8th International AIDS Conference, Toronto.
4. Barre-Sioussi F (1996). HIV as the cause of AIDS. Lancet 348: 31-35.
5. Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F (2001). Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15: 1369-1377.
6. Bartlett JA, Fath MJ, DeMasi Rc, Hermes A, Quinn J, Mondou E, Rousseau F (2006). An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 20(16): 2051-2064
7. Cains JS, Souza DMP (1998). Chemokine and HIV-1 second receptor: the therapeutic connection. Nature Med. 4: 563-568.
8. CDC. Pneumocystis pneumonia- Los Angeles. MMWR (1981). 30: 250-252.
9. Challand R, Young RJ (1990). Antiviral Chemotherapy 1996 (Spectrum Academic: Oxford). [5] DW Norbeck, Ann. Rep. Med. Chem. 25: 149.
10. Davison DK, Medinas RJ, Mosier SM, Bowling TS, Delmedico MK, Dwyer JJ, Cammack N, Greenberg ML (2006). New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249 resistant isolates. Program and abstracts of the 16th International AIDS Conference; August 13-18, 2006;Toronto, Canada. Abstract THPE0021.
11. Delmedico M, Bray B, Cammack N, Di J, Heilman D, Silinski P, Webb S, Wring S, Greenberg M (2006). Next generation fusion inhibitor candidates TRI-1144 and TRI-999 have improved pharmacokinetics: progress toward once/week dosing. Program and abstracts of the 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THAA0303.
12. Department of Health and Human Services. (2006). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. May 4, 2006. Available at: http://aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem= Gui delines&Search= Off&GuidelineID=7&ClassID=1.
13. Fanci AS (1999). The AIDS epidemic Considerations for the 21st century N. Eng. J. Med. 341: 1046-1050.
14. Gulick R, Su Z, Flexner C, Hughes M, Skolnik P, Godfrey C, Greaves W, Wilkin T, Gross R, Coakley E, Zolopa A, Hirsch M, Kuritzkes D (2006). ACTG 5211: phase II study of the safety and efficacy of vicriviroc in HIV-infected treatmentexperienced subjects. Program and abstracts of the 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada.Abstract THLB0217.
15. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, Thompson MA, Carpenter CC, Fischl MA, Gazzard BG, Gatell JM, Hirsch MS, Katzenstein DA, Richman DD, Vella S, Yeni PG, Volberding PA (2006). Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society.USA Panel. JAMA 296: 827-843.
16. HIV gene sequence Database. www.hiv.lanl.gov/content/hivdb/ALIGN_CURRENT/ ALIGN-INDEX.html
17. Janulaitis A, Petrusyte M, Maneliene Z, Klimasauskas S, Butkus V (1992). Purification and properties of Eco 57I restriction endonuclease and methylase, a prototype of a new class (type IV). Nucleic Acids Res. 20: 6043-6049.
18. Joint UNAIDS/WHO. Report on the global HIV/AIDS epidemic. Fact sheet. Geneva; UNAIDS/WHO 1997
19. Jolly D (1994). Viral vector systems for gene therapy. Cancer Gene Ther. pp. 1-599.
20. Kessler C, Manta Y (1990). Specificity of restriction endonucleases and DNA modification methyltransferases, a review gene. Gene 92:1-248.
21. Ledley TS, Ledley FD (1994). Multi-compartment, numerical model for cellular events in the pharmacokinetics of gene therapies. Hum. Gene Ther. 5:679-691.
22. Levy JA (1996). Infection by HIV: CD4 is not enough. N Engl. J Med. 336: 1528-1580.
23. Liu D, Dunn E, Unemori P, Eden C, Conant MA, Cowan MJ (2006). Safe and sustainable anti-HIV hematopoietic progenitor cell-delivered antisense: followup through month 60 from phase I trial Abstract number MOPDA07, 2006 8th International AIDS conference, Toronto.
24. Mansky LM, Temin HM (1995). Lower in-vivo mutation rate of HIV-1 than predicted from the fidelity of purified reverse transcriptase. J. Virol. 69: 5087-9094.
25. Markowitz M, Nguyen B-Y, Gotuzzo F, Mendo F, Ratanasuwan W, Kovacs C, Zhao J, Gilde L, Isaacs R, Teppler H (2006). Potent antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, as part ofcombination ART in treatment-naive HIV-1 infected patients. Program and abstracts of the 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada. Abstract THLB0214.
26. Mayer H, van der Ryst E, Saag M, Clotet B, Fatkenheuer G, Clumeck N, Turner K, Goodrich JM (2006). Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experienced subjects infected with a dual/mixed-tropic HIV-1:24-week results of a phase 2b exploratory trial. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THLB0215.
27. Meshcheryakova Y, Gashnikova N, Plyasunova O, Pokrovskaya N, Pokrovsky A, Petyovka N, Tchurikov N (2006). Inhibition of HIV-1 replication in human T cells by RNA interference Abstract MOPDA07, 2006 8th International AIDS conference, Toronto.
28. Miller AD, Miller DG, Garcia JV, Lynch CM (1993). Use of retroviral vectors for gene transfer and expression. Method Enzymol 1993: 581-559.
29. Misaki W (2005). Makerere Develops a Model for an AIDS Cure. www.aegis.org/news/nv/2005/NV050301.html
30. Murray N (2000). Type 1 Restriction systems. Sophisticated Molecular Machines (a legacy of Bertani and Weigle). Microbial Mol. Biol. Rev. 64: 412-434.
31. Nelson M, McClelland M (1991). Site specific Methylation effect on DNA modification methyltransferases and restriction endonucleases. Nucleic Acids Res. 19: 2045-2071.
32. Nelson M, Yuan R, Heywood J (1972). Bacterial Restriction Modification systems. Ann. Rev. Biochem. pp. 41:447.
33. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S (2005). TNX-355 in combination with optimized background regimen (OBR) exhibits greater antiviral activity than OBR alone in HIV treatment experienced patients. Program and abstracts of the 45th Interscience Conference of Antimicrobial Agents and Chemotherapy; Washington, DC. Abstract LB2-26.
34. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S (2006). TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase II study at 48 weeks. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract THLB0218.
35. Perelson AS, Neumann AII, Markowitz M, Leonard JM, Ho DD (1996). HIV-1 dynamics in-vivo; Virion clearance rate, infected cell life span and viral generation time. Science 271: 1582-1586.
36. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD (1997). Decay characteristic of HIV-1 infected compartments during combination therapy. Nature 387(6629): 188-191.
37. Promega Corp. http://www.promega.com/default.asp
38. Pugach P, Kuhmann S, Ketas T, Moore JP (2006). The mechanism of HIV-1 escape from small molecule CCR5 antagonists. Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract MOAA0105.
39. Radasci NW, Bickle (1996). DNA Restriction and modification. In Neidhort (ed) Escherchia coli, and salmonella. Cellular and molecular biology 2nd Edn,Washington DC. Am. Soc. Microbiol. pp 773-781,
40. Roberts RJ, Macelis D (1991). Restriction enzymes and their isoschizomes. Nuclei Acids Res. pp. 2077-2109.
41. Rosenberg YJ, Anreson AO, Pabst R (1998). HIV induced decline in CD4/CD8 ratio; viral killing or altered lymphocyte trafficking. Immunol Today. 19: 10-16.
42. Sajic R, Lee K, Asai K, Cochrane A (2006).Use of modified U1snRNAs to inhibit HIV-1replication .Abstract MOPDA01, 2006 8th International AIDS conference, Toronto. Ontario
43. Sansone A, Keung A, Tetteh E, Weisbrot H, Martinho M, Lang S, D Post, Keller R, Kraan M (2006). Vicriviroc (VCV) pharmaco-kinetics (PK): lack of impact of ritonavir (RTV)-boosted protease inhibitors (PI). Program and abstracts of the 16th International AIDS Conference; Toronto, Canada. Abstract TUPE0074.
44. UNAIDS. Report on the global HIV-AIDS epidemic July 2002.
45. Web cutter Version 2.0. http://rna.lundberg.gu.se/cutter2/
46. WHO. Removing obstacles to health development. Geneva; WHO: 1999.